ADVERTISEMENT
ADVERTISEMENT
oct4 yamanaka factor oskm ips ipsc induced pluripotent stem cell
Oct4, Considered Vital for Creating iPSCs, Actually Isn’t Needed
Dropping the transcription factor from the four so-called Yamanaka factors reduces the efficiency of inducing the production of stem cells, but the resulting cells are of greater quality.
Oct4, Considered Vital for Creating iPSCs, Actually Isn’t Needed
Oct4, Considered Vital for Creating iPSCs, Actually Isn’t Needed

Dropping the transcription factor from the four so-called Yamanaka factors reduces the efficiency of inducing the production of stem cells, but the resulting cells are of greater quality.

Dropping the transcription factor from the four so-called Yamanaka factors reduces the efficiency of inducing the production of stem cells, but the resulting cells are of greater quality.

  1. Home
  2. Subjects
  3. iPS
iPS
natural killer cells nk cell therapy product immunotherapy clinical trial
Clinical Trial Underway for a Natural Killer Cell Therapy
Chia-Yi Hou | May 7, 2019 | 3 min read
The cells, derived from induced pluripotent stem cells, are in testing as an immunotherapy for cancer patients with solid tumors.
Japan Approves iPS Cell Therapy Trial for Spinal Cord Injury
Catherine Offord | Feb 18, 2019 | 1 min read
The treatment will be tested in a handful of patients who suffered nerve damage in sports or traffic accidents.
First iPS Cell Trial for Heart Disease Raises Excitement, Concern
Katarina Zimmer | Aug 31, 2018 | 4 min read
Without knowing the cells’ mechanism of action, researchers question the best way to administer them to patients.
ADVERTISEMENT
ADVERTISEMENT